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Leukocytes undergo significant reprogramming in patients
with sepsis [1]. Compared with monocytes from healthy
subjects, monocytes from patients with severe infections
lose their capacity to mount a pro-inflammatory response
after stimulation with bacterial products. Not only do
they produce less pro-inflammatory cytokines, they also
increase their production of anti-inflammatory mediators
and receptor antagonists, such as the monocyte de-
activating interleukin (IL)-10 and IL-ra [2]. This gives the
plasma a dominant “anti-inflammatory” flavor [3]. It has
been proposed that this phenomenon is a compensatory
reaction to the initial inflammatory response [4]. We
believe that this is an essential adaptive systemic response
aimed at concentrating the inflammatory response at the
site of infection, in the organs [5]. A decreased surface
expression of major histocompatibility class II molecules
was also described in circulating monocytes from patients
with sepsis, as well as in other critically ill patients. This is
associated with an impaired antigen presentation capacity.
The association of a decreased HLA-DR expression
and a blunted pro-inflammatory cytokine production by
monocytes is also known as “immunoparalysis” [6]. The
molecular mechanisms of HLA-DR downregulation at the
surface of monocytes from critically ill patients are now
better understood. HLA-DR production is impaired, and
is retained intracellularly [7, 8, 9, 10]. Interestingly, this
monocyte phenotype can be reversed by the treatment of
septic patients with interferon-γ or granulocyte–monocyte
colony-stimulating factor [11, 12, 13]. Unfortunately,
these studies were not powered to demonstrate an im-
provement in survival in patients with severe sepsis,
nor did they show a convincing decrease in the rate of
secondary infections.
Monocyte HLA-DR expression has been reported in
40 studies in a total of over 1,400 critically ill patients [14,
15]. An association between low HLA-DR expression and
bad outcome was found in many of these studies, but not
in all. Importantly, the populations of critically ill patients
studied were quite diverse: medical, postsurgical, burns,
transplant, and trauma patients, as well as patients with
sepsis of various degrees of severity. The outcome vari-
ables measured were also numerous, including rate of sec-
ondary infections, development of shock, organ dysfunc-
tion and death. It has therefore been impossible to aggre-
gate data from the different studies and to draw a defi-
nite conclusion as to whether HLA-DR measurement of-
fers a significant benefit to the critically ill patient.
In a study reported in this issue of Intensive Care
Medicine, Monneret et al. measured the level of expres-
sion of monocyte HLA-DR and its evolution with time in
93 patients with septic shock [16]. Persisting low HLA-DR
values—defined as < 30% positive monocytes—at day
3–4 after ICU admission identified a population of patients
with a remarkably high mortality rate. Low HLA-DR was
an independent factor by multivariate analysis and was
found to be a better predictor of mortality than SAPS II
and SOFA scores. In the absence of a specific intervention
on HLA-DR expression, it is impossible to say whether
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low HLA-DR is a marker or a “mediator” of poor outcome
in patients with septic shock. Monocyte HLA-DR levels
may at best shed some light on the pathogenesis of im-
mune dysfunction of critically ill patients. In no case will
this marker—as many other markers or scores of severi-
ty—help the clinician to make radical decisions, such as
whether to withhold or withdraw treatments, for example.
Monocyte HLA-DR expression is, however, becoming
an easy and robust marker of the immune dysfunction of
critically ill patients. It could be used in the future both
for the detection of immune paralysis and as a useful
monitoring tool for interventions in immune-suppressed
critically ill patients.
This study reminds us of the three essential steps
necessary to define a biological marker as a useful marker
in our daily ICU practice. Firstly, the analytical conditions
of the test must be optimized, standardized and made
reproducible. This has been a problem for many years
with the measurement of HLA-DR expression. Incon-
sistent results rendered comparisons between centers
virtually impossible. A kit for the quantification of the
mean expression of HLA-DR in circulating monocytes
is now commercially available, which has very signifi-
cantly decreased intra- and inter-assay variability [17].
It requires access to a flow cytometer, however, and is
therefore not exactly a simple bedside test. Monneret et al.
measured HLA-DR with a non-commercial but accurate
and reproducible method [18]. Interestingly, HLA-DR was
significantly associated with outcome when these authors
expressed results as % positive monocytes, but not when
cell fluorescence was measured as “mean fluorescence in-
dex (MFI)”. Although there is no clear explanation for this
finding, this might only be due to an insufficient number of
patients to achieve significant results with MFI. It would
probably now be important to compare the method used
by Monneret et al. with that of a commercially available
quantification kit for HLA-DR expression with regard to
their respective values as a prognostic marker.
Secondly, the parameter should be tested in nor-
mal subjects and prospectively in patients with well-
characterized pathological conditions over time and with
well-defined outcomes. This step is essential to deter-
mine normal values and also significant cut-off values at
given time points during the course of the disease. The
studies should be powered such that one can rely with
sufficient confidence on the findings. HLA-DR expression
in critically ill patients is a prototypical situation where
the studies are lacking that might establish indisputable
confidence in this marker in the clinical arena. The study
by Monneret et al. does, however, add a piece to this
edifice and is quite satisfying in this regard. The authors
included a fairly homogeneous population and a rea-
sonable number of septic shock patients surviving after
48 h, measured HLA-DR at several time points during the
course of the disease, and determined a robust outcome,
mortality. A methodological weakness of this study is its
monocentric design, preventing testing of the inter-center
reproducibility of the results. Furthermore, their findings
now need to be independently validated in another cohort
of similar patients.
The final and important step is the application of the
test in “impact studies”. No clinician wants another prog-
nostic marker to test at the bedside without knowing what
he has to do with the results. Measuring this parameter
should potentially allow the clinician to modify the care
and ideally the outcome of his patient.
As said earlier, it is not conceivable that low HLA-DR
on day 3 or 4 will be used by the clinician to take dras-
tic decisions, despite its good prognostic value. However,
the results from this study permit identification of a popu-
lation of patients with septic shock that have an increased
risk of mortality, with an accuracy that is better than sever-
ity scores. It is very likely that monocyte HLA-DR expres-
sion persisting at low values at day 3 or 4 after the onset
of septic shock will identify patients with a persistent im-
mune dysfunction. These patients are probably those who
fail to clear out their primary bacterial infection and those
at risk of acquiring lethal secondary infections. Therefore,
the identification of these patients might be valuable to
reinitiate infectious work-ups, optimize the source control,
and possibly modify the antibiotic therapy. This test may
also prove very useful to select patients in future interven-
tion trials who could profit from immunomodulatory treat-
ments. Although promising as a future tool for the care
of the critically ill patient, monocyte HLA-DR expression
remains an investigational parameter, still has to be fully
validated, and needs to find its niche before it is widely
used.
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